Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 6/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916811 | 0.92 | GPR84 (0.47) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL3131647 | 0.82 | GPR84 (0.54) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL31481612 | 0.82 | GPR84 (0.54) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL827047 | 0.82 | GPR84 (0.54) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL849501 | 0.79 | CSNK2A1 (0.60) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL20671044 | 0.76 | ALDH1A1 (0.59) | AHRCYP2A6MAPK1MEN1POLB | |
| SCHEMBL8648526 | 0.75 | ALOX15 (0.50) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL2936352 | 0.75 | CSNK2A1 (0.60) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL398920 | 0.75 | CSNK2A1 (0.60) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL917519 | 0.75 | CSNK2A1 (0.55) | GPR84CSNK2A1AHRCYP2A6NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763710-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Kala Pharmaceuticals, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-104870422-B | Amine derivative or its salt | 富士胶片富山化学株式会社 | 2019-03-15 | — | — | CN | disclosed |
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2029543-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146376-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | GPR84 1242/4885CSNK2A1 44/4885AHR 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.